Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | FABP7 | O15540 | 1/20 | 0.51 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10917139 | 1.00 | RAB9A (0.54) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL16117454 | 1.00 | RAB9A (0.54) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL7897964 | 1.00 | RAB9A (0.54) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL7897961 | 1.00 | RAB9A (0.54) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL595759 | 0.97 | TSHR (0.55) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL14324086 | 0.97 | TSHR (0.55) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL595790 | 0.97 | TSHR (0.55) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL596126 | 0.97 | TSHR (0.55) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL13849249 | 0.97 | TSHR (0.55) | RAB9ATAAR1FABP7FABP5TSHR | |
| SCHEMBL16347238 | 0.95 | TSHR (0.55) | RAB9AFABP7FABP5TSHRFKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102660-B2 | Process of making prostacyclin compounds with linker thiol and pegylated forms | United Therapeutics Corporaiton (US) | 2015-08-11 | — | — | US | disclosed |
| US-20140288314-A1 | PROCESS OF MAKING PROSTACYCLIN COMPOUNDS WITH LINKER THIOL AND PEGYLATED FORMS | UNITED THERAPEUTICS CORPORATION (US) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288314-A1 | PROCESS OF MAKING PROSTACYCLIN COMPOUNDS WITH LINKER THIOL AND PEGYLATED FORMS | PTGIS, PTGIR, PTGER1 | RAB9A 3432/4885TAAR1 411/4885FABP7 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.